Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06940739 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
A Phase 1 study of Metastatic Melanoma and Unresectable Melanoma, sponsored by Iovance Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 4
- Study locations
NCT06940739: Recruiting Phase 1 study of Metastatic Melanoma and Unresectable Melanoma, sponsored by Iovance Biotherapeutics.
NCT06940739 is a Phase 1 study of Metastatic Melanoma and Unresectable Melanoma that is actively recruiting participants, run by Iovance Biotherapeutics. The registered enrollment target is 42 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (49% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06940739, a Phase 1 study of Metastatic Melanoma and Unresectable Melanoma, is actively recruiting participants, sponsored by Iovance Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.
Primary Outcome
The frequency and severity of treatment emergent adverse events and serious adverse events will be assessed when IOV-3001 administered
Conditions Studied
Interventions
- BIOLOGICAL IOV-3001
Study Locations (4)
Colorado
- SCRI Oncology Partners- Denver - Denver
North Carolina
- UNC Hospitals, The University of North Carolina at Chapel Hill - Chapel Hill
Tennessee
- Sarah Cannon Research Institute - Nashville
Queensland
- Greenslopes Private Hospital - Greenslopes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2032-07 |
| Phase | Phase 1 |
What NCT06940739 shows while recruiting
NCT06940739 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (49% lower).
The record links to 3 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 1 intervention - of which IOV-3001 is the first listed.
NCT06940739 reports a single indexed study location in Colorado, North Carolina, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06940739 about?
NCT06940739 is a clinical study titled "A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel". A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.
What is the current status of trial NCT06940739?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2025-03-11. Estimated completion is 2032-07.
What conditions does trial NCT06940739 study?
This clinical trial studies the following conditions: Metastatic Melanoma, Unresectable Melanoma, Ocular Melanoma.
What interventions are being tested in trial NCT06940739?
The interventions under investigation include: IOV-3001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06940739?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06940739 being conducted?
This trial has 4 study locations across Colorado, North Carolina, Tennessee, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06940739's enrollment target sits among peer trials
42 42nd of 91 higher than 50 of 91 other Metastatic Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
RECRUITING · Phase 1
-
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
RECRUITING · Phase 1
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
-
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI